Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED)

Phase 2TerminatedNCT00266357

H. Lundbeck A/S50 enrolled

Overview

A study to evaluate the efficacy, safety and tolerability of MK-0928 in Primary Insomnia.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Primary Insomnia

Interventions

MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose)DRUG

Placebo / Duration of Treatment: 2 days for screening periodDRUG

Eligibility

Sex: ALLMin age: 20 YearsMax age: 64 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with a diagnosis of primary insomnia Exclusion Criteria: * Patients with an active psychiatric disorder other than primary insomnia

Outcomes

Primary Outcomes

Mean of total sleep time over 2 nights.

Secondary Outcomes

Mean of other PSG sleep parameters over 2 nights, mean of subjective sleep parameters, and exploratory residual effect.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.